John Overdeck’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.7M | Buy |
785,208
+245,339
| +45% | +$3.4M | 0.01% | 1400 |
|
|
2026
Q1 | $7.9M | Buy |
539,869
+396,271
| +276% | +$6.32M | 0.01% | 1596 |
|
|
2025
Q4 | $1.11M | Sell |
143,598
-59,762
| -29% | -$471K | ﹤0.01% | 2845 |
|
|
2025
Q3 | $1.5M | Sell |
203,360
-20,553
| -9% | -$105K | ﹤0.01% | 2321 |
|
|
2025
Q2 | $896K | Sell |
223,913
-84,437
| -27% | -$307K | ﹤0.01% | 2310 |
|
|
2025
Q1 | $981K | Buy |
308,350
+278,046
| +918% | +$1.31M | ﹤0.01% | 2189 |
|
|
2024
Q4 | $162K | Sell |
30,304
-41,248
| -58% | -$308K | ﹤0.01% | 2901 |
|
|
2024
Q3 | $378K | Buy |
71,552
+23,766
| +50% | +$85.3K | ﹤0.01% | 2585 |
|
|
2024
Q2 | $87K | Sell |
47,786
-54,663
| -53% | -$102K | ﹤0.01% | 2838 |
|
|
2024
Q1 | $182K | Sell |
102,449
-78,255
| -43% | -$163K | ﹤0.01% | 2734 |
|
|
2023
Q4 | $318K | Sell |
180,704
-92,303
| -34% | -$135K | ﹤0.01% | 2672 |
|
|
2023
Q3 | $399K | Buy |
273,007
+18,753
| +7% | +$39.7K | ﹤0.01% | 2374 |
|
|
2023
Q2 | $582K | Buy |
254,254
+50,207
| +25% | +$104K | ﹤0.01% | 2264 |
|
|
2023
Q1 | $186K | Sell |
204,047
-77,140
| -27% | -$60.2K | ﹤0.01% | 2575 |
|
|
2022
Q4 | $239K | Sell |
281,187
-148,521
| -35% | -$131K | ﹤0.01% | 2334 |
|
|
2022
Q3 | $352K | Buy |
429,708
+68,674
| +19% | +$65.5K | ﹤0.01% | 1911 |
|
|
2022
Q2 | $357K | Sell |
361,034
-143,121
| -28% | -$176K | ﹤0.01% | 1957 |
|
|
2022
Q1 | $827K | Sell |
504,155
-426,292
| -46% | -$780K | ﹤0.01% | 1797 |
|
|
2021
Q4 | $2.24M | Buy |
930,447
+789,992
| +562% | +$3.06M | ﹤0.01% | 1828 |
|
|
2021
Q3 | $680K | Sell |
140,455
-169,198
| -55% | -$501K | ﹤0.01% | 2983 |
|
|
2021
Q2 | $827K | Sell |
309,653
-39,103
| -11% | -$108K | ﹤0.01% | 2642 |
|
|
2021
Q1 | $1.07M | Buy |
+348,756
| New | +$1.26M | ﹤0.01% | 2243 |
|
|
2020
Q3 | – | Sell |
-50,776
| Closed | -$138K | – | 3165 |
|
|
2020
Q2 | $138K | Sell |
50,776
-48,482
| -49% | -$143K | ﹤0.01% | 2741 |
|
|
2020
Q1 | $209K | Sell |
99,258
-9,341
| -9% | -$37.9K | ﹤0.01% | 2624 |
|
|
2019
Q4 | $591K | Buy |
108,599
+44,551
| +70% | +$156K | ﹤0.01% | 2652 |
|
|
2019
Q3 | $193K | Buy |
64,048
+17,144
| +37% | +$72K | ﹤0.01% | 3202 |
|
|
2019
Q2 | $175K | Sell |
46,904
-16,957
| -27% | -$66.4K | ﹤0.01% | 3120 |
|
|
2019
Q1 | $257K | Sell |
63,861
-4,839
| -7% | -$20.4K | ﹤0.01% | 2694 |
|
|
2018
Q4 | $252K | Buy |
+68,700
| New | +$468K | ﹤0.01% | 2576 |
|
Other funds holding CRVS
ASP
John Overdeck's CRVS Position: Q2 2026 in Review
John Overdeck increased its Corvus Pharmaceuticals (CRVS) stake by 45% in Q2 2026, buying an estimated $3.4M and bringing the position to 785,208 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #1400.
John Overdeck first reported a position in CRVS in Q4 2018 and has held it in 29 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.
- John Overdeck held 785,208 shares of Corvus Pharmaceuticals worth $11.7M as of Q2 2026.
- John Overdeck bought 245,339 Corvus Pharmaceuticals shares in Q2 2026, an estimated $3.4M.
- Corvus Pharmaceuticals made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1400 holding.
- John Overdeck first reported a position in Corvus Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
- 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.